Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.16199 | DOI Listing |
Pharmaceutics
November 2024
Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília 70910-900, DF, Brazil.
Although androgenic alopecia is the most prevalent among non-cicatricial alopecia, it still lacks an effective and safe treatment. Dutasteride (DUT) shows promising results in hair regrowth; however, oral DUT intake causes serious sexual adverse events. Hence, we produced liposomes with different bilayer structures and evaluated the capability of such systems in increasing DUT accumulation in the hair follicles.
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Dermatology, Medical University of Warsaw, Nowogrodzka 59 Str., 02-014 Warsaw, Poland.
: Minoxidil, in addition to its vasodilatory effect, has also immunomodulatory properties that may be partially responsible for its efficacy in alopecia areata. The aim of the study was to evaluate the efficacy of monotherapy with topical or oral minoxidil in alopecia areata. : A systematic review and meta-analysis of the efficacy of monotherapy with minoxidil in alopecia areata was conducted following the PRISMA guidelines.
View Article and Find Full Text PDFLife (Basel)
December 2024
Institute of Dermatology, Department of Medical Area, University of Udine, 33100 Udine, Italy.
This literature review aims to comprehensively evaluate the clinical and dermoscopic presentations of common pediatric diseases among children with skin of color (SoC) while also addressing potential variations based on racial backgrounds. This review encompasses various conditions, such as nevi subtypes, viral infections, infestations, and inflammatory dermatoses, as well as hair diseases and abnormal vascular formations, occurring in pediatric populations. Overall, we identified 7 studies on nevi subtypes, 24 studies on skin infections, 6 on inflammatory dermatoses, 10 on hair diseases and disorders, and 14 on miscellaneous disorders that also satisfied our SoC- and race-specific criteria.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Dermatology and Venereology Department, Eskisehir Osmangazi University, Eskisehir, Turkey.
Background: Seborrheic dermatitis (SD) is a chronic, inflammatory disease characterized by unknown etiopathogenesis. It affects skin areas rich in sebaceous glands. There are strong data on the relationship between nutrition habits, body mass index (BMI), psychoemotional status, and sebaceous gland diseases such as acne, rosacea, and androgenetic alopecia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!